Optic neuritis and multiple sclerosis

Archives of Ophthalmology

Volumn 121, Issue 7, 2003, Pages 1039-1040

  Levin, Leonard A ^a   Lessell, Simmons ^b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE;

BRAIN INJURY; CLINICAL FEATURE; CLINICAL TRIAL; COHORT ANALYSIS; DIAGNOSTIC TEST; DISEASE COURSE; DISEASE SEVERITY; EDITORIAL; FOLLOW UP; HUMAN; IMMUNE SYSTEM; IMMUNOMODULATION; MEDICAL EXAMINATION; MULTIPLE SCLEROSIS; NERVE FIBER DEGENERATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NERVE DISEASE; PRIORITY JOURNAL; RISK FACTOR; SYMPTOMATOLOGY;

HUMANS; MULTIPLE SCLEROSIS; OPTIC NEURITIS; RISK FACTORS;

EID: 0037925587     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: 10.1001/archopht.121.7.1039     Document Type: Editorial

References (10)

1. Beck RW, Cleary PA, Anderson MM Jr, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis: the Optic Neuritis Study Group. N Engl J Med. 1992;326:581-588.
2. Optic Neuritis Study Group. High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol. 2003;121:944-949.
3. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50:121-127.
4. Rizzo JF, Lessell S. Optic neuritis and ischemic optic neuropathy: overlapping clinical profiles. Arch Ophthalmol. 1991;109:1668-1672.
5. Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain. 1997;120(pt 3):393-399.
6. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med. 1998;338:278-285.
7. De Stefano N, Matthews PM, Fu L, et al. Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis: results of a longitudinal magnetic resonance spectroscopy study. Brain. 1998;121 (pt 8):1469-1477.
8. Brex PA, Jenkins R, Fox NC, et al. Detection of ventricular enlargement in patients at the earliest clinical stage of MS. Neurology. 2000;54:1689-1691.
9. Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis: ALS/Riluzole Study Group. N Engl J Med. 1994;330:585-591.
10. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003;348:1333-1341.